Overall, our findings provide evidence for a distinct mechanism of drug-tolerance and residual disease centered on FAK-YAP/TEAD signaling axis activation that promotes cancer cell survival and potentially tumor immune evasion during targeted therapy. The gene discussed is PTK2; the disease is neoplasm.